IASLC World Conference on Lung Cancer | Conference

COVID-19 Leads to High Hospitalization and Mortality in Malignant Pleural Mesothelioma

September 8th 2021

Approximately 20% of patients with malignant pleural mesothelioma were diagnosed with COVID-19 during the first year of the pandemic at the Vall d’Hebron University Hospital, leading to a high hospitalization and mortality rate.

Tislelizumab Plus Chemotherapy Elicits PFS Benefit in Advanced Squamous NSCLC

September 8th 2021

Tislelizumab plus chemotherapy demonstrated clinically meaningful improvements in progression-free survival vs standard of care chemotherapy as a first-line treatment for patients with stage IIIB and those with stage IV advanced squamous non–small cell lung cancer.

Pelcitoclax/Osimertinib Combo Shows Preliminary Effiacy in EGFR+ NSCLC

September 8th 2021

The combination of osimertinib plus pelcitoclax demonstrated an acceptable safety profile and preliminary efficacy at the recommended phase 2 dose in patients with EGFR-positive non–small cell lung cancer that is resistant to third-generation EGFR inhibitors or treatment naïve.

Pralsetinib Elicits Promising Activity in Advanced RET Fusion+ NSCLC

September 8th 2021

In patients with advanced RET fusion–positive non-small cell lung cancer, pralsetinib demonstrated promising results regardless of previous therapies.

Mobocertinib Shows Superior PROs in Previously Treated EGFR Exon 20+ Metastatic NSCLC

September 8th 2021

Mobocertinib improved patient-reported outcomes in those with previously treated non–small cell lung cancer whose tumors harbored EGFR exon 20 insertion mutations.

Dr. Majem on the Safety Profile of Osimertinib in EGFR+ NSCLC

February 24th 2021

Margarita Majem, MD, PhD, discusses the safety profile of osimertinib in patients with EGFR-mutated non–small cell lung cancer.

Dr. Li on the Efficacy of Sotorasib in KRAS+ Advanced NSCLC

February 24th 2021

Bob T. Li, MD, PhD, MPH, discusses the efficacy of sotorasib in patients with KRAS G12C–mutated advanced non-small cell lung cancer, as demonstrated in phase 2 cohort results of the phase 2 CodeBreaK 100 trial.

Repotrectinib Elicits Early Responses in ROS1+ Metastatic NSCLC

January 31st 2021

January 31, 2021 - Repotrectinib, a next-generation ROS1 and TRK TKI, has demonstrated encouraging objective responses with acceptable tolerability in patients with ROS1 fusion–positive non–small cell lung cancer.

Atezolizumab Combo Demonstrates Survival Benefit for ES-SCLC in Maintenance Phase

January 31st 2021

January 31, 2021 - The latest data from the IMpower133 trial shows that maintenance therapy with atezolizumab plus carboplatin and etoposide improves overall survival and progression-free survival for patients with extensive stage small cell lung cancer.

Updated Data Show Durable Response for Tepotinib in MET exon 14 Skipping NSCLC

January 31st 2021

Tepotinib demonstrated durable clinical activity in patients with MET exon 14 skipping non‒small cell lung cancer.

Dr. Cho on the Updated Efficacy of Repotrectinib in TKI-Naïve ROS1+ NSCLC

January 31st 2021

Byoung Chul Cho, MD, PhD, discusses the updated efficacy reported with repotrectinib in TKI-naïve patients with ROS1-positive non–small cell lung cancer.

Dr. Reck on the Efficacy of Maintenance Atezolizumab in ES-SCLC

January 31st 2021

Martin Reck, MD, PhD, discusses the efficacy of maintenance atezolizumab in patients with extensive-stage small cell lung cancer.

Neoadjuvant Atezolizumab Elicits Impressive Responses in Resectable NSCLC

January 30th 2021

January 30, 2021 - Neoadjuvant atezolizumab followed by surgery resulted in a major pathologic response in 21% of patients with resectable stage IB-IIIB non–small cell lung cancer, as well as significant surgical outcomes with a high rate of R0 resection.

CONFIRM Data Push Nivolumab into Treatment Landscape for Relapsed Mesothelioma

January 30th 2021

January 30, 2021 - Data from the phase 3 CONFIRM trial support single-agent nivolumab as an effective treatment approach for patients with previously treated malignant mesothelioma.

Dr. Liu on Emerging Data With Novel ADCs in NSCLC

January 30th 2021

Stephen Liu, MD, discusses emerging research on antibody–drug conjugate in non–small cell lung cancer that were presented during the 2020 World Conference on Lung Cancer.

Dr. Velcheti on the Results of the CodeBreaK 100 Primary Analysis in KRAS G12C+ NSCLC

January 30th 2021

Vamsidhar Velcheti, MD, discusses the results from the primary analysis of the CodeBreaK 100, which examined sotorasib in patients with KRAS G12C–mutated non–small cell lung cancer.

HRQoL Maintained With Adjuvant Osimertinib in EGFR+ NSCLC

January 30th 2021

January 29, 2021 - Health-related quality of life was maintained for patients with EGFR-positive non–small cell lung cancer who received treatment with adjuvant osimertinib versus placebo, with no clinically meaningful differences noted between study arms.

Pembrolizumab/Ipilimumab Combo Does Not Improve Survival, Shows Higher Toxicity in PD-L1+ NSCLC

January 30th 2021

January 29, 2021 - Pembrolizumab plus ipilimumab did not improve survival and had higher rates of toxicity versus pembrolizumab monotherapy as a first-line treatment for patients with metastatic non–small cell lung cancer who had a PD-L1 tumor proportion score of 50% or greater, and did not harbor EGFR or ALK aberrations.

Mobocertinib Shows Encouraging ORR in EGFR Exon 20–Mutant Advanced NSCLC

January 30th 2021

January 29, 2021 — Mobocertinib (formerly TAK-788) demonstrated clinically meaningful benefit and a manageable safety profile in previously treated patients with metastatic non–small cell lung cancer who have EGFR exon 20 insertion mutations.

Datopotamab Deruxtecan Elicits Early Antitumor Activity in Relapsed/Refractory Metastatic NSCLC

January 29th 2021

January 29, 2021 - The investigational antibody-drug conjugate datopotamab deruxtecan demonstrated encouraging antitumor activity and a manageable safety profile in patients with advanced or metastatic non–small cell lung cancer.